Evgenia Preka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Evgenia Preka has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Olivia Boyer
Néphrologie Pédiatrique Centre de Référence MARHEA Institut Imagine Hôpital Universitaire Necker-Enfants Malades Assistance Publique -Hôpitaux de Paris (APHP) INSERM U1163 UPC Paris France
6 shared publications Mathilde Grapin
Pediatric Nephrology, Reference Center for Idiopathic Nephrotic Syndrome in Children and Adults, University Hospital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris (APHP), Imagine Institute, INSERM U1163, Paris Cité University, Paris, France
3 shared publications- Kitty J. Jager
ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam , Amsterdam
2 shared publications Laureline Berteloot
Imagerie Pédiatrique, Hôpital Universitaire Necker‐Enfants Malades, APHP, Institut Imagine, INSERM U1163 Université Paris Cité Paris France
2 shared publicationsMargaux Boistault
Néphrologie Pédiatrique, Centre de Référence MARHEA, Hôpital Universitaire Necker‐Enfants Malades, Assistance Publique – Hôpitaux de Paris (APHP), Institut Imagine, INSERM U1163 Université Paris Cité Paris France
2 shared publicationsMarina Avramescu
Néphrologie Pédiatrique, Centre de Référence MARHEA, Hôpital Universitaire Necker‐Enfants Malades, Assistance Publique – Hôpitaux de Paris (APHP), Institut Imagine, INSERM U1163 Université Paris Cité Paris France
2 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Elsevier in Kidney International
Long-term outcomes of childhood nephrotic syndrome
- 26 September 2026
- Published by Elsevier in Kidney International
Open AccessLong-term outcomes of childhood nephrotic syndrome
- 23 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (10) , 2176-2193
Normalization of nCounter Gene Expression Data Alters Molecular Diagnostics in Kidney Transplantation
Key Points: Normalization methods affected the performance of gene-based diagnostic classifiers for kidney transplant rejection across a large multicenter cohort. Complex normalization reduced classifier performance by overcorrecting signal, while simpler methods preserved rejection signature and key robustness. By identifying optimal normalization methods, this work advances a standardized preprocessing framework for molecular diagnostics in transplantation. Background: The Banff 2022 classification endorses intragraft gene expression profiling using the Banff Human Organ Transplant (B-HOT) consensus gene panel for rejection diagnosis. However, lack of standardized analytical pipelines, including data normalization, limits clinical implementation, with its effect on diagnostic performance yet to be determined. Methods: We evaluated ten normalization methods in 868 kidney allograft biopsies from nine European and North American centers, all Banff-graded and B-HOT–profiled on nCounter, comprising derivation ( n =441), internal ( n =186), and external ( n =241) validation cohorts. Each method was assessed through its downstream impact on ( 1 ) gene count stability, ( 2 ) differential expression and cross-platform concordance with RNA sequencing (RNA-seq) data, and ( 3 ) discrimination and calibration of predictive models for antibody-mediated rejection (AMR) and T -cell–mediated rejection (TCMR). Results: Most methods improved count stability and showed high concordance with RNA-seq for overall gene expression. They also produced robust differential expression signatures consistent with those detected by RNA-seq, except for RUVSeq and RCRNorm , which identified fewer differentially expressed genes and showed lower concordance. In the overall validation cohort ( n =427), diagnostic performance was consistently high across nSolver -based approaches, nanostringr , NanoStringDiff , MetaNorm , and RCRNormFast (AMR, area under the ROC curve [AUROC], 0.88–0.91; area under precision-recall curves [AUPRC], 0.86–0.89; TCMR AUROC, 0.90–0.92; AUPRC, 0.78–0.83). Performance declined with RCRNorm (AMR AUROC/AUPRC, 0.55/0.41; TCMR, 0.53/0.18) and, for TCMR, with RUVSeq (AUROC, 0.84–0.85; AUPRC, 0.64–0.65). Calibration was satisfactory for most methods, except for RCRNorm and for TCMR models after RUVSeq . Conclusions: Normalization choice significantly impacted gene expression profiles and diagnostic classifier performance. Most methods, including nSolver-based pipelines, achieved robust discrimination for both AMR and TCMR. Complex methods, including RCRNorm, and RUVSeq for TCMR, reduced performance, with simpler approaches consistently outperforming them for B-HOT–based molecular diagnostics.
- 23 April 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (10) , 2176-2193
Normalization of nCounter Gene Expression Data Alters Molecular Diagnostics in Kidney Transplantation
Key Points: Normalization methods affected the performance of gene-based diagnostic classifiers for kidney transplant rejection across a large multicenter cohort. Complex normalization reduced classifier performance by overcorrecting signal, while simpler methods preserved rejection signature and key robustness. By identifying optimal normalization methods, this work advances a standardized preprocessing framework for molecular diagnostics in transplantation. Background: The Banff 2022 classification endorses intragraft gene expression profiling using the Banff Human Organ Transplant (B-HOT) consensus gene panel for rejection diagnosis. However, lack of standardized analytical pipelines, including data normalization, limits clinical implementation, with its effect on diagnostic performance yet to be determined. Methods: We evaluated ten normalization methods in 868 kidney allograft biopsies from nine European and North American centers, all Banff-graded and B-HOT–profiled on nCounter, comprising derivation ( n =441), internal ( n =186), and external ( n =241) validation cohorts. Each method was assessed through its downstream impact on ( 1 ) gene count stability, ( 2 ) differential expression and cross-platform concordance with RNA sequencing (RNA-seq) data, and ( 3 ) discrimination and calibration of predictive models for antibody-mediated rejection (AMR) and T -cell–mediated rejection (TCMR). Results: Most methods improved count stability and showed high concordance with RNA-seq for overall gene expression. They also produced robust differential expression signatures consistent with those detected by RNA-seq, except for RUVSeq and RCRNorm , which identified fewer differentially expressed genes and showed lower concordance. In the overall validation cohort ( n =427), diagnostic performance was consistently high across nSolver -based approaches, nanostringr , NanoStringDiff , MetaNorm , and RCRNormFast (AMR, area under the ROC curve [AUROC], 0.88–0.91; area under precision-recall curves [AUPRC], 0.86–0.89; TCMR AUROC, 0.90–0.92; AUPRC, 0.78–0.83). Performance declined with RCRNorm (AMR AUROC/AUPRC, 0.55/0.41; TCMR, 0.53/0.18) and, for TCMR, with RUVSeq (AUROC, 0.84–0.85; AUPRC, 0.64–0.65). Calibration was satisfactory for most methods, except for RCRNorm and for TCMR models after RUVSeq . Conclusions: Normalization choice significantly impacted gene expression profiles and diagnostic classifier performance. Most methods, including nSolver-based pipelines, achieved robust discrimination for both AMR and TCMR. Complex methods, including RCRNorm, and RUVSeq for TCMR, reduced performance, with simpler approaches consistently outperforming them for B-HOT–based molecular diagnostics.
- Open Access
- 16 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1744-1752
Effectiveness of Mycophenolate Mofetil Trough Level Monitoring in Children with Relapsing Nephrotic Syndrome
Key Points: Therapeutic drug monitoring on the basis of mycophenolic acid (MPA) trough levels is associated with higher effectiveness of mycophenolate mofetil in maintaining remission in children with steroid-dependent nephrotic syndrome/frequently relapsing nephrotic syndrome. Dose adjustments on the basis of MPA trough levels personalize treatment, are associated with higher effectiveness, and help minimize potential toxicity. Maintaining MPA trough levels above 2.9 µ g/ml provides a relapse-free survival rate more than 85%, similar to that of more toxic drugs. Background: The effectiveness of therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) trough levels in children with steroid-dependent nephrotic syndrome (SDNS)/frequently relapsing nephrotic syndrome (FRNS) treated with mycophenolate mofetil (MMF) has not been adequately assessed. Methods: We performed an international, retrospective study including children with SDNS/FRNS treated with MMF as the first-line steroid-sparing agent and a follow-up of more than 6 months. Patients were categorized into two groups: TDM, if MPA trough levels were monitored, and no-TDM, if not. In the TDM group, MMF doses were adjusted to maintain MPA trough levels of more than 3 µ g/ml, unless toxicity occurred. The primary outcome was relapse-free survival. Results: A total of 167 patients were observed, 90 in the TDM group and 77 in the no-TDM group. Relapse-free survival over the total follow-up was significantly longer in the TDM group ( P = 0.001, log-rank test) with an estimated relapse-free survival at 6 months of 73% for the TDM group and 55% for the no-TDM group. After correcting for potential confounders, the association remained statistically significant ( P < 0.001). TDM patients also received lower doses of prednisone after MMF introduction. In the TDM group, children were more likely to modify their initial dose (90% versus 9%; P < 0.001). Although MMF dose was not associated with relapse (median 1186 versus 1298 mg/m 2 ; P = 0.14), MPA trough levels were significantly higher in children who did not relapse (4.0 versus 2.7 µ g/ml, P = 0.001). Among children maintaining mean MPA levels more than 2.9 µ g/ml, relapse-free survival at 6 months was 86%. Reported side effects were similar in both groups. Conclusions: Monitoring MPA trough levels was associated with an approximately 20% higher MMF effectiveness in maintaining remission at 6 months in children with SDNS/FRNS. Personalized MMF dosing, adjusted to maintain MPA levels more than 2.9 µ g/ml, was both safe and effective. We recommend including MPA trough level monitoring in future studies comparing MMF with other steroid-sparing agents in children with SDNS/FRNS.
- 16 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1744-1752
Open AccessEffectiveness of Mycophenolate Mofetil Trough Level Monitoring in Children with Relapsing Nephrotic Syndrome
Key Points: Therapeutic drug monitoring on the basis of mycophenolic acid (MPA) trough levels is associated with higher effectiveness of mycophenolate mofetil in maintaining remission in children with steroid-dependent nephrotic syndrome/frequently relapsing nephrotic syndrome. Dose adjustments on the basis of MPA trough levels personalize treatment, are associated with higher effectiveness, and help minimize potential toxicity. Maintaining MPA trough levels above 2.9 µ g/ml provides a relapse-free survival rate more than 85%, similar to that of more toxic drugs. Background: The effectiveness of therapeutic drug monitoring (TDM) of mycophenolic acid (MPA) trough levels in children with steroid-dependent nephrotic syndrome (SDNS)/frequently relapsing nephrotic syndrome (FRNS) treated with mycophenolate mofetil (MMF) has not been adequately assessed. Methods: We performed an international, retrospective study including children with SDNS/FRNS treated with MMF as the first-line steroid-sparing agent and a follow-up of more than 6 months. Patients were categorized into two groups: TDM, if MPA trough levels were monitored, and no-TDM, if not. In the TDM group, MMF doses were adjusted to maintain MPA trough levels of more than 3 µ g/ml, unless toxicity occurred. The primary outcome was relapse-free survival. Results: A total of 167 patients were observed, 90 in the TDM group and 77 in the no-TDM group. Relapse-free survival over the total follow-up was significantly longer in the TDM group ( P = 0.001, log-rank test) with an estimated relapse-free survival at 6 months of 73% for the TDM group and 55% for the no-TDM group. After correcting for potential confounders, the association remained statistically significant ( P < 0.001). TDM patients also received lower doses of prednisone after MMF introduction. In the TDM group, children were more likely to modify their initial dose (90% versus 9%; P < 0.001). Although MMF dose was not associated with relapse (median 1186 versus 1298 mg/m 2 ; P = 0.14), MPA trough levels were significantly higher in children who did not relapse (4.0 versus 2.7 µ g/ml, P = 0.001). Among children maintaining mean MPA levels more than 2.9 µ g/ml, relapse-free survival at 6 months was 86%. Reported side effects were similar in both groups. Conclusions: Monitoring MPA trough levels was associated with an approximately 20% higher MMF effectiveness in maintaining remission at 6 months in children with SDNS/FRNS. Personalized MMF dosing, adjusted to maintain MPA levels more than 2.9 µ g/ml, was both safe and effective. We recommend including MPA trough level monitoring in future studies comparing MMF with other steroid-sparing agents in children with SDNS/FRNS.
- 3 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (4) , 1181-1190
Emergency peritoneal dialysis via haemodialysis catheter for paediatric acute kidney injury in low-income settings: a life-saving procedure
Background The percutaneous insertion of a peritoneal dialysis (PD) catheter by a nephrologist offers a plausible alternative to surgical insertion, improving access to dialysis. We report the experience of the paediatric nephrology unit in Dakar, Senegal, initiating PD for children with acute kidney injury (AKI), using a haemodialysis catheter inserted via a modified Seldinger technique. This approach was chosen due to its availability and cost-free provision, addressing resource constraints effectively. Methods This pilot case series study describes a cohort of nine children with AKI managed using this innovative technique between March and October 2024 in Dakar, Senegal. Results Nine children, including two neonates with life-threatening AKI, were included. Mean age was 4.5 years, with a male-to-female ratio of 1.25. Infections accounted for 44.4% (n = 4) of the cases. Catheter insertion in the peritoneal cavity was successful in eight out of nine cases; one mispositioned catheter (case 9) was removed and excluded from analysis. During the first week, no cases of bleeding or dialysate leakage occurred at the insertion site. Peritonitis was observed in two cases after > 2 weeks. Of the eight children with successful catheter placement, five stabilised on PD (62.5%); and of those five, two (40%) fully recovered kidney function. Three children (37.5%) succumbed to septic shock from the underlying infection. Conclusions Within the “Saving Young Lives” programme, our small case series showed that a haemodialysis catheter can feasibly deliver paediatric emergency PD in Dakar. Safety, efficacy, and programme-level impact must be confirmed in larger, multi-centre studies before wider training and implementation. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 3 September 2025
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (4) , 1181-1190
Emergency peritoneal dialysis via haemodialysis catheter for paediatric acute kidney injury in low-income settings: a life-saving procedure
Background The percutaneous insertion of a peritoneal dialysis (PD) catheter by a nephrologist offers a plausible alternative to surgical insertion, improving access to dialysis. We report the experience of the paediatric nephrology unit in Dakar, Senegal, initiating PD for children with acute kidney injury (AKI), using a haemodialysis catheter inserted via a modified Seldinger technique. This approach was chosen due to its availability and cost-free provision, addressing resource constraints effectively. Methods This pilot case series study describes a cohort of nine children with AKI managed using this innovative technique between March and October 2024 in Dakar, Senegal. Results Nine children, including two neonates with life-threatening AKI, were included. Mean age was 4.5 years, with a male-to-female ratio of 1.25. Infections accounted for 44.4% (n = 4) of the cases. Catheter insertion in the peritoneal cavity was successful in eight out of nine cases; one mispositioned catheter (case 9) was removed and excluded from analysis. During the first week, no cases of bleeding or dialysate leakage occurred at the insertion site. Peritonitis was observed in two cases after > 2 weeks. Of the eight children with successful catheter placement, five stabilised on PD (62.5%); and of those five, two (40%) fully recovered kidney function. Three children (37.5%) succumbed to septic shock from the underlying infection. Conclusions Within the “Saving Young Lives” programme, our small case series showed that a haemodialysis catheter can feasibly deliver paediatric emergency PD in Dakar. Safety, efficacy, and programme-level impact must be confirmed in larger, multi-centre studies before wider training and implementation. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- Top Cited Papers
- 14 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2161-2173
Reshaping transplantation with AI, emerging technologies and xenotransplantation
Organ transplantation remains the sole definitive treatment for many forms of end-stage organ failure, yet donor organ shortages impose life-threatening delays for thousands of patients worldwide. Mechanical supports and dialysis provide only temporary respite, while lifelong immunosuppression poses additional risks—including infections, malignancies and considerable healthcare costs. Recent innovations hold promise for overcoming these barriers. Artificial intelligence tools increasingly guide organ allocation decisions by integrating clinical, demographic and immunological data. They also refine rejection monitoring, personalize immunosuppressive regimens and facilitate virtual patient simulations. Meanwhile, xenotransplantation has progressed through multi-gene editing of donor pigs and improved immunosuppressive protocols, edging closer to mitigating hyperacute rejection in kidney, heart and liver grafts. In parallel, regenerative medicine approaches—spanning stem cell therapies, three-dimensional organoids and three-dimensional bioprinting—are poised to create patient-specific tissues that reduce rejection and enhance graft longevity. Biomaterials and cell encapsulation further offer localized immunosuppression, potentially streamlining post-transplant care. Yet widespread clinical adoption requires rigorous validation, ethical frameworks and interdisciplinary collaboration. By combining artificial intelligence-guided diagnostics, innovative organ engineering and advanced immunotherapies, transplant medicine can progress toward a future in which organ scarcity is alleviated, patient outcomes are optimized and healthcare systems operate with greater efficiency.
- 14 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2161-2173
Top Cited PapersReshaping transplantation with AI, emerging technologies and xenotransplantation
Organ transplantation remains the sole definitive treatment for many forms of end-stage organ failure, yet donor organ shortages impose life-threatening delays for thousands of patients worldwide. Mechanical supports and dialysis provide only temporary respite, while lifelong immunosuppression poses additional risks—including infections, malignancies and considerable healthcare costs. Recent innovations hold promise for overcoming these barriers. Artificial intelligence tools increasingly guide organ allocation decisions by integrating clinical, demographic and immunological data. They also refine rejection monitoring, personalize immunosuppressive regimens and facilitate virtual patient simulations. Meanwhile, xenotransplantation has progressed through multi-gene editing of donor pigs and improved immunosuppressive protocols, edging closer to mitigating hyperacute rejection in kidney, heart and liver grafts. In parallel, regenerative medicine approaches—spanning stem cell therapies, three-dimensional organoids and three-dimensional bioprinting—are poised to create patient-specific tissues that reduce rejection and enhance graft longevity. Biomaterials and cell encapsulation further offer localized immunosuppression, potentially streamlining post-transplant care. Yet widespread clinical adoption requires rigorous validation, ethical frameworks and interdisciplinary collaboration. By combining artificial intelligence-guided diagnostics, innovative organ engineering and advanced immunotherapies, transplant medicine can progress toward a future in which organ scarcity is alleviated, patient outcomes are optimized and healthcare systems operate with greater efficiency.
- Open Access
- 12 February 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (8) , 1580-1589
Access to kidney transplantation and re-transplantation from childhood to adulthood: long-term data from the ERA Registry
Background and hypothesis: Knowledge regarding access to first kidney transplantation (KT) and subsequent KT in patients commencing kidney replacement therapy (KRT) in childhood is limited. Methods: Using European Renal Association (ERA) Registry data, we investigated European patients who started KRT below 20 years of age between 1978 and 2019. Access and determinants to first, second, and third KT were assessed using multivariable Cox regression. Results: Totals of 12 623, 4077, and 1186 patients were included while awaiting first, second, and third KT, at median ages of 13.8 (IQR: 7.5–17.4), 20.9 (IQR: 16.5–26.1), and 26.6 (IQR: 20.3–32.8) years, respectively. During the study period, overall access was 87.8%, 72.7%, and 60.5% for first, second, and third KT, respectively, and median time to each KT was 0.9 (IQR: 0.2–2.1), 1.9 (0.6–4.5), and 2.6 (IQR: 1.0–5.3) years. Younger age at KRT initiation (aHR 0-4 vs. 10–14 years: 0.54; 95%CI: 0.51–0.57) and female sex (HR: 0.94; 95%CI: 0.90–0.98) were associated with lower access to first KT. KT candidates between 15 and 19 years had lower access to first and second KT (aHR: 0.69; 95%CI: 0.66–0.73, and aHR: 0.70; 95%CI: 0.61–0.81) compared to 10–14 year-olds. Compared to CAKUT, glomerulonephritis patients had lower access to KT (aHR: 0.75; 95%CI: 0.71–0.80 for first, aHR: 0.89; 95%CI: 0.81–0.98 for second, and aHR: 0.80; 95%CI: 0.66–0.97 for third KT). Similarly, patients with primary renal diseases with high risk of recurrence, had lower chances of receiving a first and second KT (aHR: 0.80; 95%CI: 0.76–0.85 for first, aHR: 0.86; 95%CI: 0.78–0.95 for second KT). Access to re-transplantation was also higher with previous pre-emptive KT and previous graft survival exceeding 5 years. Conclusion: Our study highlights KT access disparities particularly for females, the youngest recipients, high-risk age (15–19 years), and diseases with recurrence risk. Notably, pre-emptive transplants and enduring previous grafts offer advantages regarding re-transplantation.
- 12 February 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (8) , 1580-1589
Open AccessAccess to kidney transplantation and re-transplantation from childhood to adulthood: long-term data from the ERA Registry
Background and hypothesis: Knowledge regarding access to first kidney transplantation (KT) and subsequent KT in patients commencing kidney replacement therapy (KRT) in childhood is limited. Methods: Using European Renal Association (ERA) Registry data, we investigated European patients who started KRT below 20 years of age between 1978 and 2019. Access and determinants to first, second, and third KT were assessed using multivariable Cox regression. Results: Totals of 12 623, 4077, and 1186 patients were included while awaiting first, second, and third KT, at median ages of 13.8 (IQR: 7.5–17.4), 20.9 (IQR: 16.5–26.1), and 26.6 (IQR: 20.3–32.8) years, respectively. During the study period, overall access was 87.8%, 72.7%, and 60.5% for first, second, and third KT, respectively, and median time to each KT was 0.9 (IQR: 0.2–2.1), 1.9 (0.6–4.5), and 2.6 (IQR: 1.0–5.3) years. Younger age at KRT initiation (aHR 0-4 vs. 10–14 years: 0.54; 95%CI: 0.51–0.57) and female sex (HR: 0.94; 95%CI: 0.90–0.98) were associated with lower access to first KT. KT candidates between 15 and 19 years had lower access to first and second KT (aHR: 0.69; 95%CI: 0.66–0.73, and aHR: 0.70; 95%CI: 0.61–0.81) compared to 10–14 year-olds. Compared to CAKUT, glomerulonephritis patients had lower access to KT (aHR: 0.75; 95%CI: 0.71–0.80 for first, aHR: 0.89; 95%CI: 0.81–0.98 for second, and aHR: 0.80; 95%CI: 0.66–0.97 for third KT). Similarly, patients with primary renal diseases with high risk of recurrence, had lower chances of receiving a first and second KT (aHR: 0.80; 95%CI: 0.76–0.85 for first, aHR: 0.86; 95%CI: 0.78–0.95 for second KT). Access to re-transplantation was also higher with previous pre-emptive KT and previous graft survival exceeding 5 years. Conclusion: Our study highlights KT access disparities particularly for females, the youngest recipients, high-risk age (15–19 years), and diseases with recurrence risk. Notably, pre-emptive transplants and enduring previous grafts offer advantages regarding re-transplantation.
- 26 September 2024
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (6) , 649-657
Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis
Distal renal tubular acidosis (dRTA) is characterized by a primary defect in proton secretion by α-intercalated cells of the collecting duct, leading to impaired urine acidification and resulting in metabolic acidosis, hypokalemia, and hypercalciuria. Inherited forms of dRTA are currently associated with variants in five genes (SLC4A1, ATP6V1B1, ATP6V0A4, FOXI1, and WDR72), each being associated with specific extra-renal manifestations. Acquired forms can result from autoimmune diseases or drug side effects. Classical complications include nephrolithiasis, nephrocalcinosis, reduced glomerular filtration rate (GFR), bone demineralization, and growth failure. Treatment focuses on correcting the acid–base imbalance through alkali supplementation (potassium, sodium, or magnesium bicarbonate or citrate) to reduce renal disease progression and promote normal growth and mineralization. Traditional treatments (alkali and potassium supplementation) often suffer from poor adherence due to frequent day and night administrations, gastrointestinal discomfort, and unpleasant taste. A novel investigational drug, ADV7103, which contains potassium citrate and potassium bicarbonate in an extended-release formulation, has recently been approved by the European Medicine Agency (EMA) for dRTA. Recent studies support its use as a first-line treatment, given its efficacy and safety profile.
- 26 September 2024
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (6) , 649-657
Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis
Distal renal tubular acidosis (dRTA) is characterized by a primary defect in proton secretion by α-intercalated cells of the collecting duct, leading to impaired urine acidification and resulting in metabolic acidosis, hypokalemia, and hypercalciuria. Inherited forms of dRTA are currently associated with variants in five genes (SLC4A1, ATP6V1B1, ATP6V0A4, FOXI1, and WDR72), each being associated with specific extra-renal manifestations. Acquired forms can result from autoimmune diseases or drug side effects. Classical complications include nephrolithiasis, nephrocalcinosis, reduced glomerular filtration rate (GFR), bone demineralization, and growth failure. Treatment focuses on correcting the acid–base imbalance through alkali supplementation (potassium, sodium, or magnesium bicarbonate or citrate) to reduce renal disease progression and promote normal growth and mineralization. Traditional treatments (alkali and potassium supplementation) often suffer from poor adherence due to frequent day and night administrations, gastrointestinal discomfort, and unpleasant taste. A novel investigational drug, ADV7103, which contains potassium citrate and potassium bicarbonate in an extended-release formulation, has recently been approved by the European Medicine Agency (EMA) for dRTA. Recent studies support its use as a first-line treatment, given its efficacy and safety profile.
- Open Access
- 5 July 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (11) , 2466-2472
Vesico‐ureteral reflux diagnosis after initial kidney abscess: Results from a Paediatric Tertiary Hospital
Aims: Guidelines regarding voiding cystourethrogram (VCUG) indications following a paediatric kidney abscess are lacking. This study evaluates vesicoureteral reflux (VUR) prevalence and outcome after a first kidney abscess.Methods: This retrospective study included all children presenting to a tertiary paediatric reference centre with de‐novo kidney abscesses from 2011 to 2022, diagnosed through imaging (ultrasonography or computed tomography). VCUG's clinical utility was assessed by exploring outcomes related to interventions.Results: Among the 17 patients (median age 9 months, IQR; 6 months–6 years), VCUG identified VUR in 7 (41%; 95% CI: 18–65%), including two with grade IV–V. Median abscess size was 19 mm (IQR; 14–27). 7/8 (88%) children with DMSA scan presented scars, including 4 with hypofunctioning (20%–44%), and one with a non‐functioning kidney. Scarring on the DMSA scan was similar regardless of identified VUR. Six children had subsequent pyelonephritis. Three of the remaining 11 had grade I–III and two IV–V VUR. Surgery was required in four children overall: three for recurrent pyelonephritis and one for high‐grade VUR and scars.Conclusion: Among initial kidney abscess cases, 41% had VUR, similar to children experiencing their first uncomplicated pyelonephritis. VCUG results guided antibiotic prophylaxis but not surgical decisions. We suggest considering VCUG following recurrent pyelonephritis/kidney abscess and/or kidney scarring.
- 5 July 2024
- Published by Wiley in Acta Paediatrica
- Vol. 113 (11) , 2466-2472
Open AccessVesico‐ureteral reflux diagnosis after initial kidney abscess: Results from a Paediatric Tertiary Hospital
Aims: Guidelines regarding voiding cystourethrogram (VCUG) indications following a paediatric kidney abscess are lacking. This study evaluates vesicoureteral reflux (VUR) prevalence and outcome after a first kidney abscess.Methods: This retrospective study included all children presenting to a tertiary paediatric reference centre with de‐novo kidney abscesses from 2011 to 2022, diagnosed through imaging (ultrasonography or computed tomography). VCUG's clinical utility was assessed by exploring outcomes related to interventions.Results: Among the 17 patients (median age 9 months, IQR; 6 months–6 years), VCUG identified VUR in 7 (41%; 95% CI: 18–65%), including two with grade IV–V. Median abscess size was 19 mm (IQR; 14–27). 7/8 (88%) children with DMSA scan presented scars, including 4 with hypofunctioning (20%–44%), and one with a non‐functioning kidney. Scarring on the DMSA scan was similar regardless of identified VUR. Six children had subsequent pyelonephritis. Three of the remaining 11 had grade I–III and two IV–V VUR. Surgery was required in four children overall: three for recurrent pyelonephritis and one for high‐grade VUR and scars.Conclusion: Among initial kidney abscess cases, 41% had VUR, similar to children experiencing their first uncomplicated pyelonephritis. VCUG results guided antibiotic prophylaxis but not surgical decisions. We suggest considering VCUG following recurrent pyelonephritis/kidney abscess and/or kidney scarring.
- Open Access
- 27 June 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 109 (6) , 264-270
Fifteen-minute consultation: Empowering children, young people and families through shared decision-making: a practical guide
Shared decision-making (SDM) is a collaborative approach to healthcare decision-making that involves patients and healthcare professionals working together to make decisions that are informed by the best available medical evidence, as well as the patient’s values, preferences and goals. The importance of SDM and the intricate interplay among parents, children and young people (CYP), and healthcare professionals are increasingly acknowledged as the crucial aspects of delivering high-quality paediatric care. While there is a substantial evidence base for SDM improving knowledge and reducing decisional conflict, the evidence for long-term measures such as improved health outcomes is limited and mainly inconclusive. To support healthcare teams in implementing SDM, the authors offer a practical guide to enhance decision-making processes and empower CYP and their families.
- 27 June 2024
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 109 (6) , 264-270
Open AccessFifteen-minute consultation: Empowering children, young people and families through shared decision-making: a practical guide
Shared decision-making (SDM) is a collaborative approach to healthcare decision-making that involves patients and healthcare professionals working together to make decisions that are informed by the best available medical evidence, as well as the patient’s values, preferences and goals. The importance of SDM and the intricate interplay among parents, children and young people (CYP), and healthcare professionals are increasingly acknowledged as the crucial aspects of delivering high-quality paediatric care. While there is a substantial evidence base for SDM improving knowledge and reducing decisional conflict, the evidence for long-term measures such as improved health outcomes is limited and mainly inconclusive. To support healthcare teams in implementing SDM, the authors offer a practical guide to enhance decision-making processes and empower CYP and their families.
- Open Access
- 15 November 2023
- Published by Springer Nature in Research Square
Clinical utility of voiding cystourethrogramfollowing kidney abscess in children.
Background: Limited research on paediatric kidney abscesses exists, and international guidelines on whether this should be an indication for systematic voiding cystourethrogram (VCUG) are lacking. This study evaluates VCUG’s clinical utility after initial kidney abscess presentation in otherwise healthy children. Methods: This retrospective study included all children presenting to a tertiary paediatric reference centre with a first kidney abscess over one decade (2011-2022). Results: Among the 17 patients (median age 9 months, IQR; 6 months-6 years), VCUG identified vesicoureteral reflux (VUR) in five (29%; 95%CI: 13-53%), including two with grade IV-V. Treatment consisted of 10-21 days of intravenous antibiotics (5 days of bitherapy) followed by oral treatment for 2-6 weeks. Median abscess size was 19mm (IQR; 14-27). 8/17 (47%) children presented focal areas of hypoperfusion on ultrasound, including one case of renal atrophy. Three of six children with DMSA scan showed hypofunctioning (33-44%), and one had a non-functioning kidney. The proportion of children with scars on the DMSA scan was similar, regardless of identified VUR. Seven children had subsequent pyelonephritis; three with uropathy underwent surgery (one circumcision, one ureteric reimplantation, and one nephrectomy). 10/17 had no subsequent pyelonephritis, including three with VUR grade I-III. Conclusions: Among initial kidney abscess cases, 29% had VUR, similar to children experiencing their first uncomplicated pyelonephritis. Surgery was mainly indicated for recurrent pyelonephritis with kidney scarring, regardless of VCUG results. Conversely, VCUG guided prophylactic antibiotherapy. We recommend employing similar VCUG indications for pyelonephritis or abscess after a second febrile UTI or if imaging suggests high-grade VUR or kidney scaring.
- 15 November 2023
- Published by Springer Nature in Research Square
Open AccessClinical utility of voiding cystourethrogramfollowing kidney abscess in children.
Background: Limited research on paediatric kidney abscesses exists, and international guidelines on whether this should be an indication for systematic voiding cystourethrogram (VCUG) are lacking. This study evaluates VCUG’s clinical utility after initial kidney abscess presentation in otherwise healthy children. Methods: This retrospective study included all children presenting to a tertiary paediatric reference centre with a first kidney abscess over one decade (2011-2022). Results: Among the 17 patients (median age 9 months, IQR; 6 months-6 years), VCUG identified vesicoureteral reflux (VUR) in five (29%; 95%CI: 13-53%), including two with grade IV-V. Treatment consisted of 10-21 days of intravenous antibiotics (5 days of bitherapy) followed by oral treatment for 2-6 weeks. Median abscess size was 19mm (IQR; 14-27). 8/17 (47%) children presented focal areas of hypoperfusion on ultrasound, including one case of renal atrophy. Three of six children with DMSA scan showed hypofunctioning (33-44%), and one had a non-functioning kidney. The proportion of children with scars on the DMSA scan was similar, regardless of identified VUR. Seven children had subsequent pyelonephritis; three with uropathy underwent surgery (one circumcision, one ureteric reimplantation, and one nephrectomy). 10/17 had no subsequent pyelonephritis, including three with VUR grade I-III. Conclusions: Among initial kidney abscess cases, 29% had VUR, similar to children experiencing their first uncomplicated pyelonephritis. Surgery was mainly indicated for recurrent pyelonephritis with kidney scarring, regardless of VCUG results. Conversely, VCUG guided prophylactic antibiotherapy. We recommend employing similar VCUG indications for pyelonephritis or abscess after a second febrile UTI or if imaging suggests high-grade VUR or kidney scaring.